FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma.

ERJ Open Res · 2026 · PMC12926823 · PMID 41736737

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

Despite this, improvements in pre-BD FEV 1 with astegolimab failed to reach significance but were numerically greatest among patients with low eosinophil levels.

also in 4,113 other papers

did not reach statistical significanceno p-value reported

The primary end-point evaluating the effect of tozorakimab versus placebo on clinic pre-BD FEV 1 at week 16 did not reach statistical significance in the ITT population.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.